SCHEMBL29831718

SCHEMBL29831718

C[C@@H](OCc1ccccc1)[C@H](NC(=O)[C@H](CCCCNC(=O)OCc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)OC(C)(C)C)[C@@H](C)OCc1ccccc1)[C@@H](C)OCc1ccccc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 2/20 0.49
KLK5 Q9Y337 2/20 0.49
CPB1 P15086 1/20 0.47
CPB2 Q96IY4 1/20 0.47
MAPT P10636 1/20 0.46
FOLH1 Q04609 2/20 0.45
ITGB3 P05106 1/20 0.45
ITGA2B P08514 1/20 0.45
PSMB5 P28074 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PTGER4 P35408 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29942383 0.96 KLK7 (0.49) KLK7KLK5CPB1CPB2MAPT
SCHEMBL29831604 0.93 KLK7 (0.52) KLK7KLK5CPB1CPB2MAPT
SCHEMBL29832010 0.90 KLK7 (0.49) KLK7KLK5CPB1CPB2MAPT
SCHEMBL30804252 0.89 KLK7 (0.51) KLK7KLK5CPB1CPB2MAPT
SCHEMBL29832684 0.88 KLK7 (0.52) KLK7KLK5CPB1CPB2MAPT
SCHEMBL29831602 0.87 CPB1 (0.47) CPB1CPB2FOLH1PSMB5PTGER4
SCHEMBL29831802 0.86 CPB1 (0.46) CPB1CPB2FOLH1PSMB5PTGER4
SCHEMBL29942304 0.86 CPB1 (0.47) CPB1CPB2FOLH1PSMB5PTGER4
SCHEMBL29832150 0.86 CPB1 (0.52) CPB1CPB2FOLH1PSMB5PTGER4
SCHEMBL29832028 0.85 CPB1 (0.45) CPB1CPB2FOLH1PSMB5PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213645-A1 PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE L-Base Co., Ltd. (KR) 2025-07-03 US disclosed
EP-4062974-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L BASE CO LTD (KR) 2024-05-08 EP disclosed
EP-4335452-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-03-13 EP disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
WO-2023043271-A1 METHOD FOR CHARACTERIZING RESPONDER TO CAGE INHIBITOR FOR CANCER THERAPY 주식회사 엘베이스 2023-03-23 WO disclosed
WO-2023043261-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG 주식회사 엘베이스 2023-03-23 WO disclosed
WO-2023043269-A1 PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE 주식회사 엘베이스 2023-03-23 WO disclosed
WO-2022203219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER 주식회사 엘베이스 2022-09-29 WO disclosed
EP-4062974-A2 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co.,Ltd. (KR) 2022-09-28 EP disclosed
WO-2022197100-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG 주식회사 엘베이스 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER VIP, QPCT, TPT1 KLK7 25/4885KLK5 148/4885CPB1 894/4885
US-20250213645-A1 PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE ATG7, CCL11, ATG13 KLK7 780/4885KLK5 1177/4885CPB1 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.